Silence Therapeutics (NASDAQ: SLN) is the subject of a $20.00 per share offer from Merck KGaA, aligning with a Jefferies price target. The proposed acquisition values Silence Therapeutics at $1.3 billion, leading to a significant surge in its stock price. A legal investigation is underway to…
Top Stock Gainers: Silence Therapeutics Leads on Merck Acquisition Silence Therapeutics (NASDAQ: SLN) surged after Merck KGaA agreed to acquire the company for approximately $1.30 billion in equity value. Disc Medicine (NASDAQ: IRON) rallied after its Phase 3 APOLLO trial met all primary and…
Every article on every company, fresh through the day, plus search for any ticker. Pop in your email to unlock it.
You'll get Gro's newsletter too. Leave any time in one click.
Articles from Financial Modeling Prep.
